RxDoctor Payments Data

Anas Alani, MD

Cardiovascular Disease · Loma Linda, CANPI 1154633709

Payments from drug & device makers

$477in general payments, 2019–2025

Across 17 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$126
  • Novartis$125
  • Edwards Lifesciences$104
  • Medtronic$69
  • Regeneron Healthcare Solutions, Inc.$19
  • Johnson & Johnson$19
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$45896%
  • Education$194%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$477 in reported general payments places this provider in the 25th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$116,375
Medicare patients
820
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$84,194
EntrestoSacubitril/Valsartan54$59,078
FarxigaDapagliflozin Propanediol54$49,519
XareltoRivaroxaban37$29,276
BrilintaTicagrelor13$13,559
JardianceEmpagliflozin14$8,698
VascepaIcosapent Ethyl17$6,741
Metoprolol Succinate236$2,737
Nifedipine ErNifedipine68$2,298
Atorvastatin Calcium168$1,716
Fenofibrate11$1,566
Rosuvastatin Calcium90$1,417
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$1,049
Losartan Potassium142$985
Bumetanide15$946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$125$59,07854 claims
Johnson & JohnsonXarelto$19$29,27637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →